SHA: 601089

Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against the assertion that its generic version of AstraZeneca’s (AZ, NASDAQ: AZN) type 2 diabetes therapy, Forxiga (dapagliflozin), infringed upon a patent listed by AstraZeneca on the Center for Drug Evaluation (CDE)’s drug patent registration platform,…